Eintrag weiter verarbeiten
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth F...
Gespeichert in:
| Zeitschriftentitel: | The Oncologist |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | The Oncologist, 16, 2011, 5, S. 632-640 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
Beaumont, Jennifer L. Butt, Zeeshan Baladi, Jeanfrancois Motzer, Robert J. Haas, Tomas Hollaender, Norbert Kay, Andrea Cella, David Beaumont, Jennifer L. Butt, Zeeshan Baladi, Jeanfrancois Motzer, Robert J. Haas, Tomas Hollaender, Norbert Kay, Andrea Cella, David |
|---|---|
| author |
Beaumont, Jennifer L. Butt, Zeeshan Baladi, Jeanfrancois Motzer, Robert J. Haas, Tomas Hollaender, Norbert Kay, Andrea Cella, David |
| spellingShingle |
Beaumont, Jennifer L. Butt, Zeeshan Baladi, Jeanfrancois Motzer, Robert J. Haas, Tomas Hollaender, Norbert Kay, Andrea Cella, David The Oncologist Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy Cancer Research Oncology |
| author_sort |
beaumont, jennifer l. |
| spelling |
Beaumont, Jennifer L. Butt, Zeeshan Baladi, Jeanfrancois Motzer, Robert J. Haas, Tomas Hollaender, Norbert Kay, Andrea Cella, David 1083-7159 1549-490X Oxford University Press (OUP) Cancer Research Oncology http://dx.doi.org/10.1634/theoncologist.2010-0299 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose.</jats:title> <jats:p>A phase III, randomized, double-blind, placebo-controlled trial was conducted in patients with metastatic renal cell carcinoma. The focus of this paper is to evaluate the patient-reported outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods.</jats:title> <jats:p>Patients were randomly assigned (2:1) to receive oral everolimus 10 mg once daily or placebo. The Functional Assessment of Cancer Therapy Kidney Symptom Index—Disease-Related Symptoms (FKSI-DRS) and European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 were administered before randomization and on day 1 of each cycle. The FKSI-DRS and the EORTC QLQ-C30 Physical Functioning and Global Quality of Life scores were the primary endpoints examined. Longitudinal models were used to compare treatment arms. Sensitivity analyses were conducted to explore the impact of missing data assumptions.</jats:p> </jats:sec> <jats:sec> <jats:title>Results.</jats:title> <jats:p>Longitudinal trends for FKSI-DRS scores did not differ by treatment arm. Taking nonignorable missing data into account, there were significant differences between treatment arms in the trend over time for physical functioning and global quality of life, with the everolimus arm exhibiting greater decreases. All three of these measures of health-related quality of life were significantly related to progression-free survival.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions.</jats:title> <jats:p>There was no evidence of a difference between everolimus and placebo in longitudinal patterns of disease-related symptoms, and little difference between the arms in physical functioning or global quality of life trends. This supports the conclusion that delay in tumor progression demonstrated by everolimus is associated with minimal impact on symptoms, physical functioning, or quality of life, as reported by patients.</jats:p> </jats:sec> Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy The Oncologist |
| doi_str_mv |
10.1634/theoncologist.2010-0299 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTAtMDI5OQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTAtMDI5OQ |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 |
| imprint |
Oxford University Press (OUP), 2011 |
| imprint_str_mv |
Oxford University Press (OUP), 2011 |
| issn |
1083-7159 1549-490X |
| issn_str_mv |
1083-7159 1549-490X |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
beaumont2011patientreportedoutcomesinaphaseiiistudyofeverolimusversusplaceboinpatientswithmetastaticcarcinomaofthekidneythathasprogressedonvascularendothelialgrowthfactorreceptortyrosinekinaseinhibitortherapy |
| publishDateSort |
2011 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
The Oncologist |
| source_id |
49 |
| title |
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_unstemmed |
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_full |
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_fullStr |
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_full_unstemmed |
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_short |
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_sort |
patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1634/theoncologist.2010-0299 |
| publishDate |
2011 |
| physical |
632-640 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Purpose.</jats:title>
<jats:p>A phase III, randomized, double-blind, placebo-controlled trial was conducted in patients with metastatic renal cell carcinoma. The focus of this paper is to evaluate the patient-reported outcomes.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods.</jats:title>
<jats:p>Patients were randomly assigned (2:1) to receive oral everolimus 10 mg once daily or placebo. The Functional Assessment of Cancer Therapy Kidney Symptom Index—Disease-Related Symptoms (FKSI-DRS) and European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 were administered before randomization and on day 1 of each cycle. The FKSI-DRS and the EORTC QLQ-C30 Physical Functioning and Global Quality of Life scores were the primary endpoints examined. Longitudinal models were used to compare treatment arms. Sensitivity analyses were conducted to explore the impact of missing data assumptions.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results.</jats:title>
<jats:p>Longitudinal trends for FKSI-DRS scores did not differ by treatment arm. Taking nonignorable missing data into account, there were significant differences between treatment arms in the trend over time for physical functioning and global quality of life, with the everolimus arm exhibiting greater decreases. All three of these measures of health-related quality of life were significantly related to progression-free survival.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions.</jats:title>
<jats:p>There was no evidence of a difference between everolimus and placebo in longitudinal patterns of disease-related symptoms, and little difference between the arms in physical functioning or global quality of life trends. This supports the conclusion that delay in tumor progression demonstrated by everolimus is associated with minimal impact on symptoms, physical functioning, or quality of life, as reported by patients.</jats:p>
</jats:sec> |
| container_issue |
5 |
| container_start_page |
632 |
| container_title |
The Oncologist |
| container_volume |
16 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792341567932989448 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:21:56.497Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Patient-Reported+Outcomes+in+a+Phase+III+Study+of+Everolimus+Versus+Placebo+in+Patients+with+Metastatic+Carcinoma+of+the+Kidney+That+Has+Progressed+on+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+Therapy&rft.date=2011-05-01&genre=article&issn=1549-490X&volume=16&issue=5&spage=632&epage=640&pages=632-640&jtitle=The+Oncologist&atitle=Patient-Reported+Outcomes+in+a+Phase+III+Study+of+Everolimus+Versus+Placebo+in+Patients+with+Metastatic+Carcinoma+of+the+Kidney+That+Has+Progressed+on+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+Therapy&aulast=Cella&aufirst=David&rft_id=info%3Adoi%2F10.1634%2Ftheoncologist.2010-0299&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792341567932989448 |
| author | Beaumont, Jennifer L., Butt, Zeeshan, Baladi, Jeanfrancois, Motzer, Robert J., Haas, Tomas, Hollaender, Norbert, Kay, Andrea, Cella, David |
| author_facet | Beaumont, Jennifer L., Butt, Zeeshan, Baladi, Jeanfrancois, Motzer, Robert J., Haas, Tomas, Hollaender, Norbert, Kay, Andrea, Cella, David, Beaumont, Jennifer L., Butt, Zeeshan, Baladi, Jeanfrancois, Motzer, Robert J., Haas, Tomas, Hollaender, Norbert, Kay, Andrea, Cella, David |
| author_sort | beaumont, jennifer l. |
| container_issue | 5 |
| container_start_page | 632 |
| container_title | The Oncologist |
| container_volume | 16 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose.</jats:title> <jats:p>A phase III, randomized, double-blind, placebo-controlled trial was conducted in patients with metastatic renal cell carcinoma. The focus of this paper is to evaluate the patient-reported outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods.</jats:title> <jats:p>Patients were randomly assigned (2:1) to receive oral everolimus 10 mg once daily or placebo. The Functional Assessment of Cancer Therapy Kidney Symptom Index—Disease-Related Symptoms (FKSI-DRS) and European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 were administered before randomization and on day 1 of each cycle. The FKSI-DRS and the EORTC QLQ-C30 Physical Functioning and Global Quality of Life scores were the primary endpoints examined. Longitudinal models were used to compare treatment arms. Sensitivity analyses were conducted to explore the impact of missing data assumptions.</jats:p> </jats:sec> <jats:sec> <jats:title>Results.</jats:title> <jats:p>Longitudinal trends for FKSI-DRS scores did not differ by treatment arm. Taking nonignorable missing data into account, there were significant differences between treatment arms in the trend over time for physical functioning and global quality of life, with the everolimus arm exhibiting greater decreases. All three of these measures of health-related quality of life were significantly related to progression-free survival.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions.</jats:title> <jats:p>There was no evidence of a difference between everolimus and placebo in longitudinal patterns of disease-related symptoms, and little difference between the arms in physical functioning or global quality of life trends. This supports the conclusion that delay in tumor progression demonstrated by everolimus is associated with minimal impact on symptoms, physical functioning, or quality of life, as reported by patients.</jats:p> </jats:sec> |
| doi_str_mv | 10.1634/theoncologist.2010-0299 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTAtMDI5OQ |
| imprint | Oxford University Press (OUP), 2011 |
| imprint_str_mv | Oxford University Press (OUP), 2011 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275 |
| issn | 1083-7159, 1549-490X |
| issn_str_mv | 1083-7159, 1549-490X |
| language | English |
| last_indexed | 2024-03-01T16:21:56.497Z |
| match_str | beaumont2011patientreportedoutcomesinaphaseiiistudyofeverolimusversusplaceboinpatientswithmetastaticcarcinomaofthekidneythathasprogressedonvascularendothelialgrowthfactorreceptortyrosinekinaseinhibitortherapy |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | 632-640 |
| publishDate | 2011 |
| publishDateSort | 2011 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | The Oncologist |
| source_id | 49 |
| spelling | Beaumont, Jennifer L. Butt, Zeeshan Baladi, Jeanfrancois Motzer, Robert J. Haas, Tomas Hollaender, Norbert Kay, Andrea Cella, David 1083-7159 1549-490X Oxford University Press (OUP) Cancer Research Oncology http://dx.doi.org/10.1634/theoncologist.2010-0299 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose.</jats:title> <jats:p>A phase III, randomized, double-blind, placebo-controlled trial was conducted in patients with metastatic renal cell carcinoma. The focus of this paper is to evaluate the patient-reported outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods.</jats:title> <jats:p>Patients were randomly assigned (2:1) to receive oral everolimus 10 mg once daily or placebo. The Functional Assessment of Cancer Therapy Kidney Symptom Index—Disease-Related Symptoms (FKSI-DRS) and European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 were administered before randomization and on day 1 of each cycle. The FKSI-DRS and the EORTC QLQ-C30 Physical Functioning and Global Quality of Life scores were the primary endpoints examined. Longitudinal models were used to compare treatment arms. Sensitivity analyses were conducted to explore the impact of missing data assumptions.</jats:p> </jats:sec> <jats:sec> <jats:title>Results.</jats:title> <jats:p>Longitudinal trends for FKSI-DRS scores did not differ by treatment arm. Taking nonignorable missing data into account, there were significant differences between treatment arms in the trend over time for physical functioning and global quality of life, with the everolimus arm exhibiting greater decreases. All three of these measures of health-related quality of life were significantly related to progression-free survival.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions.</jats:title> <jats:p>There was no evidence of a difference between everolimus and placebo in longitudinal patterns of disease-related symptoms, and little difference between the arms in physical functioning or global quality of life trends. This supports the conclusion that delay in tumor progression demonstrated by everolimus is associated with minimal impact on symptoms, physical functioning, or quality of life, as reported by patients.</jats:p> </jats:sec> Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy The Oncologist |
| spellingShingle | Beaumont, Jennifer L., Butt, Zeeshan, Baladi, Jeanfrancois, Motzer, Robert J., Haas, Tomas, Hollaender, Norbert, Kay, Andrea, Cella, David, The Oncologist, Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy, Cancer Research, Oncology |
| title | Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_full | Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_fullStr | Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_full_unstemmed | Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_short | Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| title_sort | patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy |
| title_unstemmed | Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1634/theoncologist.2010-0299 |